Atopic Dermatitis Clinical Trials Market Size Report, 2032

Atopic Dermatitis Clinical Trials Market - By Molecule Type (Large, Small), Study Design (Interventional, Observational), Phase (I, II, III, IV), Mode (Outsourced, In-house), Industry (Pharma & Biotech Companies, CRO’s), Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of atopic dermatitis

3.2.1.2&nbsp;&nbsp;&nbsp;Growing investments for research and development activities

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing pipeline products for atopic dermatitis

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost associated with clinical trials

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.5.1&nbsp;&nbsp;&nbsp; Supplier power

3.5.2&nbsp;&nbsp;&nbsp; Buyer power

3.5.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.5.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.5.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Molecule Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Large molecules

5.3&nbsp;&nbsp;&nbsp; Small molecules

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Study Design, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Interventional study

6.3&nbsp;&nbsp;&nbsp; Observational study

6.4&nbsp;&nbsp;&nbsp; Expanded access study

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Phase, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Phase I

7.3&nbsp;&nbsp;&nbsp; Phase II

7.4&nbsp;&nbsp;&nbsp; Phase III

7.5&nbsp;&nbsp;&nbsp; Phase IV

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Mode, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Outsourced

8.3&nbsp;&nbsp;&nbsp; In-house

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Industry, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Contract research organizations

9.3&nbsp;&nbsp;&nbsp; Pharmaceutical and biotechnology companies

9.4&nbsp;&nbsp;&nbsp; Research and academic institutes

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Germany

10.3.2&nbsp;&nbsp;&nbsp; UK

10.3.3&nbsp;&nbsp;&nbsp; France

10.3.4&nbsp;&nbsp;&nbsp; Spain

10.3.5&nbsp;&nbsp;&nbsp; Italy

10.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; China

10.4.2&nbsp;&nbsp;&nbsp; Japan

10.4.3&nbsp;&nbsp;&nbsp; India

10.4.4&nbsp;&nbsp;&nbsp; Australia

10.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Mexico

10.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp; South Africa

10.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; BIOCYTOGEN

11.2&nbsp;&nbsp;&nbsp; Charles River Laboratories

11.3&nbsp;&nbsp;&nbsp; Hooke Laboratories, LLC

11.4&nbsp;&nbsp;&nbsp; Imavita

11.5&nbsp;&nbsp;&nbsp; Novotech

11.6&nbsp;&nbsp;&nbsp; Oncodesign services

11.7&nbsp;&nbsp;&nbsp; QIMA LTD

11.8&nbsp;&nbsp;&nbsp; Redoxis

11.9&nbsp;&nbsp;&nbsp; REPROCELL Inc.

11.10&nbsp;&nbsp;&nbsp; Syneos Health 
&nbsp;

Atopic Dermatitis Clinical Trials Market

Get a free sample of this report